Subsidies for Pharma and Biotech in Belgium

Belgium is no accident as the home of one of the densest concentrations of pharmaceutical and biotech companies in Europe. Universities like KU Leuven, UGent, UCLouvain, and VUB continuously generate spin-offs and patent portfolios.

Public funding for life sciences is deep and layered. Regional agencies like VLAIO and Innoviris provide direct project grants, while federal tax advantages and EU programs offer complementary and sometimes larger resources.

For SMEs and start-ups active in the sector, funding options are more numerous than often thought — but it takes insight into which level provides what type of support.

VLAIO offers direct grants through its O&O program for companies in Flanders conducting industrial research or experimental development. Rates reach up to 50% for SMEs in recognised industrial research projects.

Pharmaceutical companies working on new active substances, formulation technology, process optimisation, or diagnostic tools may qualify. Projects in consortium with VIB, imec, or a Flemish university typically receive an enhanced subsidy rate.

Flanders Bio, the Flemish life sciences cluster, is a useful first point of contact. Through their network you gain insight into running calls, consortium opportunities, and application pathways that fit your technology profile.

See BelGrant's VLAIO grants overview for a full list of VLAIO programs relevant to your company.

For companies established in the Brussels-Capital Region, Innoviris is the central grant body. The Explore program supports fundamental and industrial research, while Bridge funds collaborative projects between companies and knowledge institutions.

Innoviris also has specific pathways for spin-offs and scale-ups in life sciences, particularly through its Spin-off and Spin-out programs. Brussels-based biotech companies benefit from the region's multilingual networks and proximity to European institutions.

Innoviris grants are tied to an operational presence in Brussels. A company registered in Ghent but conducting R&D activities from a Brussels office may still qualify — the exact conditions depend on the program.

The partial exemption from professional withholding tax for R&D researchers is one of the most powerful but least visible benefits in the Belgian system. Companies retain up to 80% of the wage tax withheld on qualified research personnel.

The innovation income deduction (IID) allows companies to exclude 85% of qualifying patent income from their taxable base. For biotech companies working on licensing models or therapeutic patents, this is a structural advantage to integrate early into the business plan.

These benefits are not linked to a region and require no advance application with a public authority. They are claimed in the annual corporate tax return, making them more accessible than project grants.

Horizon Europe Cluster 1 (Health) is one of the most active call calendars for life sciences in Europe. Belgian companies participate as coordinators or partners in projects around oncology, rare diseases, infectious disease, and digital health.

The EIC Pathfinder funds early-stage research with transformative potential — ideal for deep tech biotech projects such as CRISPR applications, synthetic biology, or mRNA platforms.

European programs are competitive but carry a significant advantage: they impose no regional establishment conditions. A Belgian company with the right innovation proposition can maximise its chances by combining regional and European funding.

Explore innovation grants available in Belgium for a full overview of complementary regional and European programs.

Most Belgian pharma and biotech grants require registration in Belgium, performance of the R&D activity on Belgian territory, and demonstrated innovation over existing solutions. Routine product development generally does not qualify.

SMEs enjoy higher grant rates at VLAIO and Innoviris. Larger companies are better served by federal tax advantages and EU programs, where organisation size is less decisive for accessibility.

A strong application combines a scientifically grounded project description with a realistic valorisation pathway. Reviewers look for specificity — the mechanism, the target indication, the differentiation arguments, and the team capable of carrying the project.

Want to know which grants best fit your pharma or biotech company? Ask Lucas, BelGrant's AI grant assistant, for a personalised overview based on your company profile, region, and R&D stage.